SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001395064-22-000014
Filing Date
2022-01-14
Accepted
2022-01-14 06:02:02
Documents
4

Document Format Files

Seq Description Document Type Size
1 SC 13G sc13g-1_011422.htm SC 13G 86933
2 EX-99.1 exhibit991-1_011422.htm EX-99.1 2021
3 EX-99.2 exhibit992-1_011422.htm EX-99.2 9613
4 EX-99.3 exhibit993-1_011422.htm EX-99.3 9953
  Complete submission text file 0001395064-22-000014.txt   110179
Mailing Address 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Business Address 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668 81332782111
TAKEDA PHARMACEUTICAL CO LTD (Filed by) CIK: 0001395064 (see all company filings)

IRS No.: 000000000
Type: SC 13G
SIC: 2834 Pharmaceutical Preparations

Mailing Address 395 OYSTER POINT BLVD STE 217 SOUTH SAN FRANCISCO CA 94080-1930
Business Address 395 OYSTER POINT BLVD STE 217 SOUTH SAN FRANCISCO CA 94080-1930 206-913-4300
Day One Biopharmaceuticals, Inc. (Subject) CIK: 0001845337 (see all company filings)

IRS No.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92582 | Film No.: 22530374
SIC: 2834 Pharmaceutical Preparations